← Back to Search

Monoclonal Antibodies

Tozorakimab for COPD (MIRANDA Trial)

Phase 3
Recruiting
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant must be ≥ 40 years of age and capable of giving signed informed consent
Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up variable duration period up to study completion, maximum of approximately 3 years
Awards & highlights

MIRANDA Trial Summary

This trial will examine the safety and effectiveness of a new drug for people with COPD who have had 2 or more moderate or 1 severe flare-ups in the last year.

Who is the study for?
Adults over 40 with COPD, having had at least one severe or two moderate flare-ups in the past year. They must have a significant cough and phlegm, poor lung function tests but not too severe, and a history of heavy smoking. Excluded are those with asthma, serious heart or other health problems, recent infections including COVID-19 or lung resections, immune deficiencies, certain liver diseases or cancer within five years.Check my eligibility
What is being tested?
The trial is testing Tozorakimab's effectiveness for COPD symptoms against a placebo. Participants will receive injections under the skin while continuing their usual inhaler treatments. The study aims to see if Tozorakimab can reduce flare-ups and improve breathing.See study design
What are the potential side effects?
Possible side effects of Tozorakimab may include reactions at the injection site, increased risk of infections due to immune system changes, fatigue, gastrointestinal issues like diarrhea or nausea; however specific side effects will be monitored throughout the trial.

MIRANDA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 40 years or older and can sign a consent form.
Select...
I've had at least 2 moderate or 1 severe COPD flare-ups in the last year.
Select...
I have been on optimized inhaled therapy for my condition for at least 3 months.

MIRANDA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~variable duration period up to study completion, maximum of approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and variable duration period up to study completion, maximum of approximately 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
Secondary outcome measures
Annualized rate of healthcare resource utilization
Annualized rate of moderate to severe COPD exacerbations in former or current smokers.
Annualized rate of severe COPD exacerbations in former or current smokers
+17 more

MIRANDA Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TozorakimabExperimental Treatment1 Intervention
Dosing subcutaneously tozorakimab
Group II: PlaceboPlacebo Group1 Intervention
Dosing subcutaneously with equivalent volume to tozorakimab

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,272 Previous Clinical Trials
288,611,435 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What sort of adverse effects can be expected from using Tozorakimab?

"The safety of Tozorakimab has been rated as a 3 on our scale, due to the availability of evidence-based efficacy and numerous rounds confirming its security."

Answered by AI

What are the eligibility criteria for joining this clinical experiment?

"To be accepted into this medical study, patients must have a diagnosis of chronic obstructive pulmonary disease and fall within the age bracket of 40 to 80 years old. A total of 1240 participants are needed for this clinical trial."

Answered by AI

Are there remaining opportunities to enlist in this research initiative?

"It appears this particular medical trial has ceased to actively accept patients, as the latest update posted on clinicaltrials.gov was made on September 11th 2023. Nevertheless, there are a plethora of other trials recruiting at present with 524 being available right now."

Answered by AI

Are elderly participants being sought after for this experiment?

"Participants in this trial must be between 40 and 130 years old. In addition, there are 36 studies targeting minors under the age of 18 and 501 for seniors above 65 years of age."

Answered by AI

How many medical institutions are engaged in this clinical trial?

"Currently, this clinical trial is accessible at 30 sites across the region, including Newport Beach, Boynton Beach and Ormond Beach. To limit any travelling requirements associated with enrolling in the study, it is recommended to select a nearby location."

Answered by AI

Who else is applying?

What site did they apply to?
Research Site
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria

Why did patients apply to this trial?

I want to be able to breathe better. Because my breathing is slowly getting worse & I want to see if this will help!
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
2023. "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06040086.
All > Paid Studies Las Vegas > Copd
~827 spots leftby Sep 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top